North America extended its dominance in artificial intelligence (AI) hiring among pharmaceutical industry companies in the three months ending September.
The number of roles in North America made up 50.5 per cent of total AI jobs – up from 46.3 per cent in the same quarter last year.
That was followed by Asia-Pacific, which saw a 2.7 year-on-year percentage point change in AI roles.
The figures are compiled by GlobalData, who track the number of new job postings from key companies in various sectors over time. Using textual analysis, these job advertisements are then classified thematically.
GlobalData's thematic approach to sector activity seeks to group key company information by topic to see which companies are best placed to weather the disruptions coming to their industries.
These key themes, which include artificial intelligence, are chosen to cover "any issue that keeps a CEO awake at night".
By tracking them across job advertisements it allows us to see which companies are leading the way on specific issues and which are dragging their heels - and importantly where the market is expanding and contracting.
Which countries are seeing the most growth for AI roles in pharma?
The fastest growing country was the United States, which saw 46.3 per cent of all AI job adverts in the three months ending June last year, increasing to 50.5 per cent in the three months ending September this year.
That was followed by China (up 2.1 percentage points), Poland (up 1.9), and France (up 1.3).
The top country for AI roles in the pharmaceutical industry is the United States which saw 50.5 per cent of all roles in the three months ending September.
Which cities are the biggest hubs for pharma AI workers?
Some 4.2 per cent of all pharmaceutical industry AI roles were advertised in Cambridge (United States) in the three months ending September - more than any other city.
That was followed by Boston (United States) with 4.2 per cent, Cambridge (United Kingdom) with 3.9 per cent, and South San Francisco (United States) with 2.6 per cent.